Onychomycosis is one of the most common nail disorders in adults. The management of onychomycosis requires the correct mycological identification where possible, assessing disease susceptibility and risk factors and deciding what therapy options are most suitable for the clinical form of onychomycosis and aetiological agent. Currently, only a few new drugs are being developed. However, the high cost and toxicity of available drugs as well as the emergence of fungal resistance, justify, the search for new classes of antifungals or innovative therapeutic strategies. Resources of the plant world in terms of active substances used for therapeutic purposes are vast and as yet, are underestimated.
Modern Medicine – Issue 3 2020